This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Veeva Systems (VEEV) and CytomX Therapeutics (CTMX)

Tipranks - Tipranks - Fri Jun 5, 8:12AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Century Therapeutics (IPSC), Veeva Systems (VEEV) and CytomX Therapeutics (CTMX).

Claim 55% Off TipRanks

Century Therapeutics (IPSC)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Century Therapeutics on June 2 and set a price target of $8.00. The company’s shares closed last Thursday at $2.06.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -1.7% and a 42.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Maze Therapeutics, Inc., Syndax Pharmaceuticals, and Atara Biotherapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Century Therapeutics with a $5.90 average price target, implying a 185.0% upside from current levels. In a report issued on May 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Veeva Systems (VEEV)

BMO Capital analyst Sean Dodge maintained a Hold rating on Veeva Systems yesterday and set a price target of $175.00. The company’s shares closed last Thursday at $173.50, close to its 52-week low of $170.25.

According to TipRanks.com, Dodge has 0 stars on 0-5 stars ranking scale with an average return of -6.5% and a 40.3% success rate. Dodge covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Aveanna Healthcare Holdings, and Lifestance Health Group. ;'>

Veeva Systems has an analyst consensus of Moderate Buy, with a price target consensus of $239.53, implying a 34.0% upside from current levels. In a report issued on May 20, TipRanks – xAI also downgraded the stock to Hold with a $178.00 price target.

CytomX Therapeutics (CTMX)

In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on CytomX Therapeutics, with a price target of $11.00. The company’s shares closed last Thursday at $3.25.

According to TipRanks.com, Driscoll is a 4-star analyst with an average return of 6.2% and a 39.7% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Arvinas Holding Company. ;'>

CytomX Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.30.

Read More on IPSC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).